94527-46-5

Upstream product

• 38240-29-8 3-nitro-2-mercaptopyridine 
• 75903-50-3 3-nitropyridine-2-sulfonamide 
• 1071524-26-9 3-nitropyridine-2-sulfonylchloride 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 69212-31-3 benzyl 3-nitro-2-pyridyl sulfide 

Downstream Products

• 163136-90-1 3-amino-pyridothiadiazine-1,1-dioxide 
• 163137-08-4 2-METHYL-2,3-DIHYDRO-4H-PYRIDO[3,2-e][1,2,4]THIADIAZINE 1,1-DIOXIDE 
• 163136-67-2 3-METHYL-4H-PYRIDO[3,2-e][1,2,4]THIADIAZINE 1,1-DIOXIDE 
• 1071519-50-0 (1R,2S,7R,8S)-5-(1,1-dioxo-1,4-dihydro-1λ6-thia-2,4,8-triazanaphthalen-3-yl)-3-(4-fluorobenzyl)-6-hydroxy-3-azatricyclo[6.2.1.02,7]undec-5-en-4-one 

Relevant academic research and scientific papers

FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY

A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS

The invention is directed to 5,6-dihydro-lH-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

Anti-infective agents

Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

Anti-infective agents

Compounds having the formula are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.